CATB News and Press, Catabasis Pharmaceuticals Inc.

Catabasis Pharmaceuticals (CATB -3.0%) announces its new name, Astria Therapeutics. The name Astria originates from the Greek word for star, reflecting the company’s commitment to having patients serve as guiding stars. Astria expects to begin trading under the new ticker symbol '...

-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Cataba...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! The week’s almost done with just one more day of trading so let’s start it with the biggest pre-market stock movers for Friday! Source: ventdusud / Shutterstock.com But let’s not get...

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are focused on advancing the development of our lead program, QLS-215, as a differe...

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 th , 2021...

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatmen...

The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector’s long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics (SRNE) and Catabasis P...

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market lea...

Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re at the midpoint of the week now and we’re still going strong with a look at the biggest pre-market stock movers for Wednesday. Source: Shutterstock There are loads to talk about tod...